Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
ACRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.17
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.14M
Market Cap
$119.11M
Enterprise Value$125.36M
Total Cash (Recent Filing)$10.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 13, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding108,281,240
10 Day Avg. Volume1,097,403
30 Day Avg. Volume1,144,159
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.22
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.87
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$9.25Price Target Upside628.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Aclaris Therapeutics News
PremiumCompany Announcements
Aclaris Therapeutics Reports 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsACRS confirmed that clinical trial activities for the Phase 2b of trial of bosakitug in atopic dermatitis have been initiated.
Financial BackingAn $80 million private placement was announced to support the company's newly bolstered pipeline and operational efforts, showing strong investor interest and financial backing.
Pipeline StrengthThe acquisition of worldwide rights to two in-licensed biologics, BSI-045B and BSI-502, is expected to strengthen Aclaris Therapeutics Inc.'s immunology-focused pipeline.
Bears Say
Financial RiskACRS has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb, which are likely to have best-in-class potency.
Market CompetitionLegacy pipeline programs may generate additional value.
---
Ownership Overview
29.21% Insiders
5.02% Mutual Funds
0.68% Other Institutional Investors
58.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $0.95 and its highest was $5.17 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $119.11M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 18 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Feb 27, 2025. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.287 by -$0.723.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 108,281,240 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.287. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
---
Aclaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (628.35% Upside)
$9.25 (628.35% Upside)
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.45%
12-Months-Change
Fundamentals
Return on Equity
-84.46%
Trailing 12-Months
Asset Growth
10.41%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
---
ACRS Stock 12 Month Forecast
Average Price Target
$9.25
▲(628.35% Upside)
Technical Analysis
Protara Therapeutics
―
Innate Pharma
―
4D Molecular Therapeutics
―
TriSalus Life Sciences
―
Molecular Partners
―
Best Analysts Covering ACRS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-38.93%
reiterated a buy rating 4 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -38.93% per trade.
---